Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Articles
Articles
MRD-Guided Zanubrutinib, Venetoclax and Obinutuzumab Maintenance in Relapsed/Refractory CLL
ASH 2023 - CLL
Results of the phase 2 CLL2-BZAG trial indicated that MRD-guided triple combination of zanubrutinib, venetoclax, and obinutuzumab induced deep remissions in patients with R/R CLL including those previously treated with BTKi and/or venetoclax.
Read More ›
Response to Subsequent Novel Therapies and Time to Second Progression-Free Survival Event in the MURANO Trial in Patients with R/R CLL Previously Treated with Fixed-Dose Venetoclax/Rituximab
ASH 2023 - CLL
Final data from the phase 3 MURANO trial demonstrated a significantly prolonged time to second progression-free survival event in the venetoclax/rituximab arm, with high response rates achieved even by patients who subsequently received retreatment or crossed over to venetoclax-based regimens or BTKi therapy.
Read More ›
PFS Benefit with Zanubrutinib Over Bendamustine/Rituximab Across Multiple High-Risk Factors in the Phase 3 SEQUOIA Study in Patients with Treatment-Naive CLL/SLL without del(17p)
ASH 2023 - CLL
Biomarker subgroup analysis results indicate that zanubrutinib treatment was associated with superior PFS in all biomarker subgroups analyzed compared to bendamustine/rituximab in treatment-naïve patients with CLL/SLL without del(17p).
Read More ›
Updated Results of the Phase 1b BRUIN Study of Fixed-Duration Pirtobrutinib Combined with Venetoclax ± Rituximab in Relapsed/Refractory CLL
ASH 2023 - CLL
Results of the phase 1/2 BRUIN study indicate that fixed-duration pirtobrutinib combined with venetoclax ± rituximab was well tolerated and showed promising efficacy in patients with relapsed or refractory chronic lymphocytic leukemia.
Read More ›
Phase 2 Study Results of the Novel TL-895 BTK Inhibitor in Treatment-Naïve and Relapsed/Refractory CLL/SLL
ASH 2023 - CLL
Results of a phase 2 study suggests that the highly selective Bruton tyrosine kinase inhibitor TL-895 therapy led to rapid bone marrow clearance of leukemic cells to induce deeper and more durable responses, with a favorable adverse event profile in patients with treatment-naïve and relapsed/refractory CLL/SLL.
Read More ›
Longer Follow-up Results of ELEVATE-TN trial of Acalabrutinib ± Obinutuzumab Versus Obinutuzumab + Chlorambucil in Patients with Treatment-Naive CLL
ASH 2023 - CLL
Extended follow-up results of the ELEVATE-TN trial (median follow-up of 74.5 months) confirmed sustained efficacy and safety of acalabrutinib/obinutuzumab and acalabrutinib monotherapy compared to obinutuzumab/chlorambucil in patients with treatment-naïve CLL, including in patients with high-risk genetic features.
Read More ›
Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR in Previously Untreated CLL
ASH 2023 - CLL
Results of the UK FLAIR Study indicate that MRD-guided treatment duration of Ibrutinib+ venetoclax significantly improved survival outcomes compared to FCR in untreated chronic lymphocytic leukemia.
Read More ›
Updated GLOW Study Results of First-Line Fixed-Duration Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab
ASH 2023 - CLL
Longer follow-up data of the GLOW study indicate that fixed-duration ibrutinib + venetoclax shows sustained PFS superiority versus chemoimmunotherapy in patients with previously untreated CLL.
Read More ›
High Response Rates to Ibrutinib Retreatment After Relapsing with First-Line Fixed Duration Ibrutinib + Venetoclax in CLL/SLL
ASH 2023 - CLL
Updated results of the CAPTIVATE study show promising efficacy with ibrutinib-based retreatment in patients progressing on a first-line, fixed duration ibrutinib + venetoclax regimen.
Read More ›
Extended Follow-up of TRANSCEND CLL 004 Trial of Lisocabtagene Maraleucel in R/R CLL/SLL
ASH 2023 - CLL
Longer follow-up data of the TRANSCEND CLL 004 trial indicated that lisocabtagene maraleucel continued to demonstrate durable CR/CRi and high uMRD rates in patients with heavily pretreated, high-risk R/R CLL/SLL; no new safety signals emerged.
Read More ›
Page 1 of 136
1
2
3
4
5
6
7
8
9
10
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us